The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Multiple companies and organizations have announced early results about their COVID-19 vaccines. Here's what we know about ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

(Reuters) -Pfizer said on Thursday it completed an acquisition worth up to $10 billion of biotech firm Metsera after winning shareholder approval, securing a path into the fast-growing obesity ...

In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...

Pfizer announced on Sept. 30 it will participate in a new government direct-to-consumer drug sale website. TrumpRx, which is expected to launch at the beginning of next year, will allow patients to ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...

Pfizer CEO Albert Bourla speaks shakes hands with U.S. President Donald Trump in a White House event on Tuesday. President Trump and Pfizer announced a deal to cut drug pricing yesterday. And it looks ...